WHEAT RIDGE, Colo., Oct. 26, 2006 (PRIMEZONE) -- GeneThera, Inc. (OTCBB:GTHA) today announced that the Company has purchased three Tecan Freedom EVO(r) 200 systems for installation in the Company's Italian, Mexican and Colorado laboratory facilities. Once installed, GeneThera will have the ability to begin the validation process for its Mad Cow Disease Live Animal Assay as well as other veterinary diseases as previously announced.
"The Tecan product is a superior state of the art system that will allow GeneThera to streamline our live animal blood testing and allow us to automatically run our tests with 100% accuracy," said Dr. Tony Milici, CEO. "By using the Freedom EVO(r) 200 system in conjunction with the Freedom EVOware(r) software, the system will automate our application quickly and easily. The Freedom EVO(r) system will allow each lab to come on-line much sooner without the delay of training personnel on new products and procedures."
"We couldn't be happier that GeneThera has placed this order for multiple units of the Freedom EVO(r) 200 system," said Jeff Aufmann, Tecan's Vice-President of Sales. "To be able to showcase Tecan's superb product within the international labs GeneThera is putting on-line to validate their live animal testing assay and to help with the growth of this ground-breaking company is of great importance to our Company."
About GeneThera, Inc.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(tm), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne's Disease, diseases affecting cattle worldwide.
About Tecan:
Tecan (www.tecan.com) is a leading player in the Life Science supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Through its subsidiary REMP (www.remp.com) Tecan is a leading supplier of compound and sample storage, managerial and logistic solutions. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2005, Tecan achieved sales of CHF 344.9 million (USD 275.9 million; EUR 222.5 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor: 1210019).
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.